Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,636
datasets available to search
ShareScore release 0.9.0
Dataset results
1,636 results for “Head and Neck cancer”
Tumor and Blood B Cell Abundance Outperforms Established ICB Response Prediction Signatures in Head and Neck Cancer
<div> <div> <div> <div> <p>This dataset contains processed flow cytometry data and clinical information for deidentified patients from Cohort 11, as well as deconvoluted cell abundances and clinical data for deidentified patients from Cohort 10, associated with the study titled <em>"Tumor and Blood B Cell Abundance Outperforms Established Immune Checkpoint Blockade Response Prediction Signatures in Head and Neck Cancer"</em> published in <strong>Annals of Oncology (2024)</strong>. <a href="https://doi.org/10.1016/j.annonc.2024.11.008" target="_new" rel="noopener">DOI: https://doi.org/10.1016/j.annonc.2024.11.008</a>.</p> </div> </div> </div> </div> <div> <div> <div> </div> </div> </div>
Point-of-care monitoring of head and neck cancer treatment response and recurrence development using nanopore-based ctDNA consensus sequencing
<p>Circulating tumor DNA (ctDNA) in blood may become a generic biomarker for non-invasive cancer diagnosis and monitoring. However, detection of ctDNA is challenged by the presence of many circulating DNA molecules from healthy cells. We found that single ctDNA molecules can be sequenced with high accuracy by a three-step process consisting of capturing, copying and concatenation of the original double-stranded ctDNA molecules. This innovative approach - called CyclomicsSeq - is unparalleled by any other method in terms of cost-efficiency and speed, allowing point-of-care cancer diagnostics.</p> <p>Within this CPOC, subsidized by the Oncode institute, we have applied our CyclomicsSeq ctDNA test in patients with advanced head and neck cancer squamous cell carcinoma (HNSCC). Head and neck cancer (HNSCC) accounts for 380,000 cancer-related deaths worldwide. For these patients, determining whether a patient responds to the primary chemoradiation treatment is challenging, and non-responders are sometimes identified when other treatment options are no longer possible. By measuring the ctDNA levels in the blood of these patients prior to and during treatment, we aim to identify non-responders at an earlier stage.</p> <p>This dataset contains base calls of TP53 of 47 nanopore sequencing runs. We included 10 patients and 7 controls. For the patients, we have samples of multiple time points (0 = prior to treatment, 1 = 1 week after treatment initiation, etc).</p>
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance - Unpublished data
<p>Antitumor effects of valproic acid (VPA) in combination with Cisplatin/Cetuximab doublet in head and neck squamous cell carcinoma (HNSCC) models. We reported unpublished data of the effects of this combination on cell cycle and 3D cell cultures</p>
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
ClinicalTrials.gov study NCT02633800. IPD Sharing: YES. Countries: 7. Publications: 2.
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
ClinicalTrials.gov study NCT01852292. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
ClinicalTrials.gov study NCT00721799. IPD Sharing: NO. Countries: 1. Publications: 3.
PD1+CD8+ cells are an independent prognostic marker in patients with head and neck cancer
<p><strong>Data open:</strong> file with parametres used for the multivariate evaluation. </p>
Serum aminoacid levels in patients with spinocelular cancer of head and neck: anonymized dataset
<p><strong>Dataset containing analysis of free serum amino acid concentrations in patients with head and neck spinocellular tumors.</strong></p> <p>The study was conducted in accord with the Helsinki Declaration of 1964 and all subsequent revisions thereof. It was approved by the ethical committee of St. Anne’s Faculty Hospital, Brno, and by ethical committee of University Hospital Motol, Prague, Czech Republic.</p> <p>All blood samples were obtained from HNSCC patients who developed histologically verified primary HNSCC after they signed the informed consent. Blood samples were obtained by venipuncture. The blood samples were centrifuged at 3000 rpm at 4°C for 10 min within 60 min after collection. Serum was aliquoted and stored at −80°C until analysis.</p> <p>The inclusion criteria were: age 40-95 years; no prior chemotherapy; no endocrinologic or metabolic disorders; no uncontrolled hypertension or infections; normal liver, heart and kidney function; and adequate bone marrow reserve.</p> <p>Amino acid profiles were examined using ion-exchange liquid chromatography (AAA-400, Ingos, Prague, Czech Republic) with post-column derivatization by ninhydrin and absorbance detector in visible light range (IEC-Vis).</p>
Data for: HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer
<p>The membrane-associated RING-CH-type finger ubiquitin ligase MARCHF8 is a human homolog of the viral ubiquitin ligases Kaposi's sarcoma herpesvirus K3 and K5 that promote host immune evasion. Previous studies have shown that MARCHF8 ubiquitinates several immune receptors, such as the major histocompatibility complex II and CD86. While human papillomavirus (HPV) does not encode any ubiquitin ligase, the viral oncoproteins E6 and E7 are known to regulate host ubiquitin ligases. Here, we report that MARCHF8 expression is upregulated in HPV-positive head and neck cancer (HNC) patients but not in HPV-negative HNC patients compared to normal individuals. The MARCHF8 promoter is highly activated by HPV oncoprotein E6-induced MYC/MAX transcriptional activation. The knockdown of MARCHF8 expression in human HPV-positive HNC cells restores cell surface expression of the tumor necrosis factor receptor superfamily (TNFRSF) death receptors, FAS, TRAIL-R1, and TRAIL-R2, and enhances apoptosis. MARCHF8 protein directly interacts with and ubiquitinates the TNFRSF death receptors. Further, MARCHF8 knockout in mouse oral cancer cells expressing HPV16 E6 and E7 augments cancer cell apoptosis and suppresses tumor growth in vivo. Our findings suggest that HPV inhibits host cell apoptosis by upregulating MARCHF8 and degrading TNFRSF death receptors in HPV-positive HNC cells.</p>
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00798655. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00736944. IPD Sharing: NO. Countries: 1. Publications: 10.
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
ClinicalTrials.gov study NCT00076310. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
ClinicalTrials.gov study NCT01057589. IPD Sharing: Not stated. Countries: 6. Publications: 2.
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
ClinicalTrials.gov study NCT00833261. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Symptom Burden in Head and Neck Cancer
ClinicalTrials.gov study NCT01219673. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
ClinicalTrials.gov study NCT02573259. IPD Sharing: NO. Countries: 7. Publications: 3.
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
ClinicalTrials.gov study NCT00820248. IPD Sharing: NO. Countries: 1. Publications: 3.
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
ClinicalTrials.gov study NCT00392704. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
ClinicalTrials.gov study NCT01065844. IPD Sharing: NO. Countries: 1. Publications: 2.
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00956007. IPD Sharing: Not stated. Countries: 4. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.